ANXA3 and neoplasm: ANXA3 levels correlated with worse overall survival in sorafenib-treated HCC patients, and combination of anti-ANXA3 monoclonal antibody and sorafenib or regorafenib inhibited HCC tumor growth in vivo with significant increase in survival [108].